Background: As the use of opioids has increased in the USA over the past 15 years, so too have rates of neonatal abstinence syndrome (NAS). The rates of NAS are now estimated at 3.39 per 1000 live births and are associated with an average inpatient stay of 16 days. While previous studies have suggested that stringent weaning protocols decrease total opioid utilization and hospital length of stay (LOS), there is no consensus among neonatologists regarding the best treatment strategy. Research Question: Does the choice of drug in weaning protocols affect the total days of opioid treatment and/or LOS? Do treatment protocols for NAS reduce total opioid use and/or LOS? Methods: This was a multicenter, statewide, cohort study. Investigators included members of six neonatal intensivist groups representing the six regional pediatric care centers, covering 20 hospitals, across the state of Ohio. The study enrolled patients from January 2012 until July 2013 and included neonates of ≥34 weeks gestational age that were diagnosed with NAS necessitating pharmacologic management. Multiple data were collected including opioid used in the treatment of NAS, length of opioid treatment, LOS, as well as maternal factors including prenatal drug exposures (if data available), access to prenatal care, and tobacco use. Each of the neonatology groups utilized their own regional weaning protocols for management of NAS with some practitioners deviating from their respective protocols. However, some standardization of treatment was achieved utilizing the Finnegan Neonatal Abstinence Scoring Tool. Results: A total of 547 pharmacologically treated infants were included in the analysis. Of the subjects, 417 were treated based on one of six strict weaning protocols while the treatment of 130 deviated from the protocols. There were no significant baseline differences between the groups except that subjects in the protocol group were more likely to have ≥1 prenatal visit and to have been treated in a level 3 nursery (i.e., a neonatal ICU). Morphine was the exclusive opioid given to 50.8 % of subjects, 41.0 % received methadone only, and 2.7 % received buprenorphine only; 5.5 % were treated with >1 opioid. Phenobarbital was used as an adjunct in 142 subjects (115 [27.5 %] in the stringent protocol group and 27 [20.7 %] in the non-stringent protocol group, p=0.22). Using a regression model, the subjects treated with a strict weaning protocol experienced a significantly shorter length of opioid treatment (17.7 vs. 32.1 days, p<0.0001) and LOS (22.7 vs. 32.1 days p=0.004). There were no significant differences in Research Question: How to determine the safety and efficacy of adjunctive ketamine for management of severe AWS? Methods: The study was a retrospective review of adult patients administered with ketamine specifically for the management of severe AWS at a single institute over a three-year period. Outcomes included changes in BZD requirements and ketamine-related adverse reactions.
Results: Of 235 patients screened, 23 patients met study eligibility. Ketamine was initiated, primarily by medical toxicology consultation, for severe AWS as defined by either a significant BZD requirement or signs of delirium tremens. The mean time to initiation of ketamine from treatment initiation of AWS and the total duration of ketamine therapy were 33.6 and 55.8 h, respectively. Mean initial infusion rate and median total infusion rate during therapy were 0.21 and 0.20 mg/kg/h, respectively. Eight patients received a loading dose of 0.3 mg/kg. There was no change in sedation or alcohol withdrawal scores in patients within 6 h of ketamine initiation. The median change in BZD requirements at 12 and 24 h post-ketamine initiation were −40.0 and −13.3 mg, respectively. The mean time to AWS resolution was 5.6 days. There was one documented adverse reaction of oversedation requiring dose reduction.
Conclusion: Ketamine appears to reduce BZD requirements and is well tolerated at low doses. Prospective dose range evaluations in the management of AWS would be helpful in determining its place as an adjunctive agent.
Critique: The major flaws of the paper are its retrospective design, small size, and lack of a control group. While this study failed to demonstrate a statistically significant decrease in BZD requirement with ketamine, these results may be tainted by the study design. Five patients received BZD and ketamine alone, while 18 received adjunctive therapy other than ketamine, potentially masking the beneficial effect of ketamine. Additionally, the presence of potentially interfering drugs (e.g., beta blockers) was not controlled for. However, this study does suggest that ketamine is a safe adjunct in this patient population. Implication for Toxicologists: The authors describe a novel treatment adjunct using an NMDA antagonism for management of severe AWS. Unlike medications such as dexmedetomidine or haloperidol, ketamine directly targets the underlying pathophysiology of alcohol withdrawal. As evidenced in the pain literature and by anecdotal inpatient experiences, ketamine has an excellent safety profile and may be a useful adjunctive treatment in severe AWS. Background: The use of extracorporeal treatment (ECTR) for lithium toxicity is controversial due to a paucity of published literature on which a clinician can base their opinion. The varied clinical presentations for lithium toxicity make it difficult to develop specific recommendations that apply to all patients. As such, there is disagreement among medical toxicologists as to when ECTR should be initiated in patients with lithium poisoning.
Research Question: Based on a systematic review of the literature, what, if any, are the indications for extracorporeal elimination of lithium in the setting of poisoning? Methods: Multiple literature databases were searched for lithium and different modalities of ECTR. Articles were reviewed and debated by committee members representing multiple medical specialties as well as nonclinical experts. Strengths of recommendations were assigned based on a two-round voting method.
Results: There were 228 patients included in the analysis; all of whom received some type of ECTR (hemodialysis was most common). Patients were grouped based on the following types of lithium poisoning: acute/acute-on-chronic, chronic, or unknown. The mean lithium clearance was reported for different removal methods: hemodialysis, 106.9 mL/min (range 40-180); continuous renal replacement therapy clearance, 43.1 mL/min (range 19-64); peritoneal dialysis, 10.9 mL/min (range 9-14); and endogenous renal clearance, 10.6 mL/min (range 1.5-39.6). Of all included patients, 83 % were reported to have clinical improvement during or after ECTR. Kinetic grading for individual patients confirmed that lithium is highly dialyzable. Lithium rebound was reported but was attributed to delayed absorption of extended-release formulations. The number of patients who experienced this post-redistribution rebound was not reported.
Conclusion:
The workgroup recommended that ECTR be used in patients with severe lithium toxicity to minimize the length of time that the brain is exposed to toxic concentrations. ECTR should be particularly considered when there is concomitant kidney impairment, evidence of neurotoxicity, or the serum lithium concentration is >5.0 mmol/L. The current literature has shown that hemodialysis is the most effective tool to rapidly reduce serum lithium levels in poisoned patients. Critique: Despite 166 total articles included in the final analysis, there were no randomized controlled trials. Plus, there was no consideration for the potential differences between traditional and high-flux hemodialysis. Furthermore, patientlevel data were available for only 228 patients. Indeed, the highest level of evidence applied to the recommendations is 1D. The authors recognized the lack of randomized clinical trials and appropriately graded their recommendations as 1D or 2D. Implication for Toxicologists: Lithium is removed by various ECTRs, and hemodialysis is the most effective. At this time, there are incomplete data to demonstrate that extracorporeal elimination of lithium actually results in more rapid neurologic improvement or superiority of ECTR over intravenous hydration alone. Nonetheless, ECTR is potentially useful in selected patients with severe lithium toxicity and/or renal impairment.
Funding Sources None.
